MygoalMySip

  • Mutual Funds
    • Mutual Funds
    • Equity Fund
    • Debt Fund
    • Hybrid Fund
  • Stocks
    • Stocks
    • Large Cap
    • Mid Cap
    • Small Cap
  • Personal Finance
    • Personal Finance
    • Savings
    • Tax
Menu
  • Mutual Funds
    • Mutual Funds
    • Equity Fund
    • Debt Fund
    • Hybrid Fund
  • Stocks
    • Stocks
    • Large Cap
    • Mid Cap
    • Small Cap
  • Personal Finance
    • Personal Finance
    • Savings
    • Tax
My-Goal-My-Sip-Final-Logo
Search
Close
My-Goal-My-Sip-Final-Logo
  • Mutual Funds
    • Mutual Funds
    • Equity Fund
    • Debt Fund
    • Hybrid Fund
  • Stocks
    • Stocks
    • Large Cap
    • Mid Cap
    • Small Cap
  • Personal Finance
    • Personal Finance
    • Savings
    • Tax
Login or Sing up

Aurobindo Pharma: Should you invest?

March 8, 2022
in Stocks
aurobindo

About the company: Aurobindo Pharma

  • Aurobindo Pharma commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. The company became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995.
  • In addition to being the market leader in Semi-Synthetic Penicillin’s, it has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and Anti-biotics.
  • It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries. The formulation business is systematically organized with a divisional structure, and has a focused team for key international markets.
  • A well-integrated pharma company, the company features among the top 2 pharmaceutical companies in India in terms of consolidated revenues.
  • Its customers include premium multi-national companies. 
HeadquarterHyderabad
SectorHealthcare – Pharmaceuticals & Drugs

Area of Operation:

  • Aurobindo Pharma have manufacturing units in India, USA, Brazil and Portugal.
  • Among top 3 with over 60% of commercial portfolio in the US in terms of prescriptions.
  • Ranked among the top 10 generics companies in 7 countries including four of Top-5 EU countries.
  • Aurobindo exports many countries across the globe with around 90% of revenues derived from international operations.
  • Product portfolio: Oncology and Hormones, Biosimilars, Dermatology, Respiratory, Depot Injections, Vaccines, Peptides.
  • Aurobindo Pharma has a high dependence on the China market for import of Key Starting Materials (KSMs), Intermediates and Active Pharmaceutical Ingredients.
  • While their key geographies remain US and Europe, they have a growing presence in emerging markets as well like Africa, the Middle East and Russia where they are managing business by participating in Government tenders and by appointing approved distributors to expand the sales in those markets.
 MDMr. N. Govindarajan
Vice-Chairman & Whole-time DirectorMr. K. Nithyananda Reddy

Board of Committees:

Subsidiaries:

70+ subsidiary companies all around the globe.

Competitors:

  • Alkem Laboratories Ltd
  • Sun Pharmaceuticals Industries Ltd

Shareholding pattern: Aurobindo Pharma

Top Shareholdings:

  • Rpr Sons Advisors Private Limited, Mrs.P.Suneela Rani (Jointly Holding) – 33.51%
  • LIC if Inida – 5.33%
  • K Nityananda Reddy – 4.33%
  • Axis Healthcare ETF – 4.13%
  • HDFC Trustee Company Ltd – 3.59%
aurobindo

Industry Overview:

  • India enjoys an important position in the global pharmaceuticals sector, it is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the UK. Globally, India ranks 3rd in terms of pharmaceutical production by volume and 14th by value.
  • According to the Indian Economic Survey 2021, the domestic market is expected to grow 3x in the next decade. As of August 2021, CARE Ratings expect India’s pharmaceutical business to develop at an annual rate of 11% over the next two years to reach more than US $60 billion in value.

Profit and Loss Statement: Aurobindo Pharma

Consolidated P&L (Rs. Crores)

 Mar-16Mar-17Mar-18Mar-19Mar-20Mar-21
Revenue from Operations13,77214,91016,46319,56423,09924,775
Expenses10,57911,46912,69115,61218,24919,497
Operating Profit3,1933,4413,7723,9524,8495,278
Profit before tax2,7443,0613,2413,0913,7437,344
Net Profit2,0252,3022,4232,3652,8455,335
EPS in Rs34.6139.2941.3640.3648.5691.05

Key Pointers:

  1. Expenses of the company majorly include 40% Material cost and 7% Manufacturing cost.
  2. Company incurs a compartively high percentage of material cost among its peers.
  3. Strong EPS growth.
  4. Strong annual perfromance when compared to immediate peer and industry leader.
  5. Sudden high is PBT is due to some exceptional items.

Standalone Balance Sheet (In Rs. Crores)

 Mar-16Mar-17Mar-18Mar-19Mar-20Mar-21
Equity Capital595959595959
Reserves7,2299,31311,62213,83216,76621,871
Borrowings5,0413,3644,7706,9675,8265,291
Trade Payables2,4572,1552,3732,5522,5762,795
Total Liabilities15,89616,20020,94226,27128,76533,401
Fixed Assets4,1804,8346,5218,4759,3969,374
Investments123246312360555591
Other Assets 10,7459,66212,52715,76816,82720,375
Cash Equivalents8005131,2621,9572,8425,474
Loans n Advances1,0592,0992,5162,8991,7192,112
Total Assets15,89616,20020,94226,27128,76533,401

Standalone Cash Flow (in Rs. Crores)

 Mar-16Mar-17Mar-18Mar-19Mar-20Mar-21
Cash from Operating Activity142032791955165143813329
Profit from operations323234703776390548345681
Inventory-456-297-1413-886-527-1594
Receivables-11101773-68-18-656716
Working capital changes-1079583-1123-1484308-1067
Direct taxes-733-774-699-770-761-1285
Cash from Investing Activity-1446-1787-1927-2904-1563597
Fixed assets purchased-1566-1694-1530-1559-1431-1874
Investment Purchases-57-118-68-46-179-467
Other Investing Items1410-11-1239-4-29
Cash from Financing Activity365-19158641919-1947-1365
Interest Paid-84-57-74-152-127-48
Proceeds from borrowings11910213926240177
Repayment of borrowings-588-1728-937-394-1530-1137
Net Cash Flow340-4248926668712561

Financial Ratios: Aurobindo Pharma

Stock Price:

1. Current Price₹ 619.00
2. Market Cap36,603 Cr
3. Yearly fluctuation590 – 1,063

Ratios:

 P/EROCEROEOp. Margin Rev Growth
Aurobindo Pharma Ltd12.7430.33%27.81%23.60%7.26%
Alkem Laboratories Ltd21.8222.55%23.91%24.54%6.24%
Sun Pharma Industries Ltd30.655.66%4.98%27.84%2.01%

SWAT: Aurobindo Pharma

Strengths:

  1. Robust Global presence with 100% owernership in 70+ companies.
  2. Large product portfolio which is manufactured and distributed around the world.
  3. Strong EPS Growth.
  4. Solid Financials in terms of both Revenue and Profit.
  5. Exceptionally Strong Cash Flow.

Weaknesses:

  1. FIIs have substantially decreased their holdings.
  2. Compartively experiances high material cost.

Opportunities:

  1. India enjoys an important position in the global pharma sector and the business tend to develop at an annual rate of 11% over the next two years.
  2. Well built retained earnings, which can be used for further developments.
  3. Undervalued when compared to Industry P/E.

Threats:

  1. High dependence on China for imports.
  2. Aurobindo Pharma are recalling different products in the US market due to deviation from standard manufacturing norms.
Disclaimer: This shouldn’t be construed as a stock recommendation, investors discretion is advised while investing.

Read Next: Century Enka Ltd: Should you invest?

For more information, reach us at [email protected]

Team, MyGoalMySip.

Tags: FUNDSINVESTMENTMUTUAL FUNDMUTUAL FUNDSSAVINGSSTOCKS
ShareTweetPin

Related Posts

adani
Stocks

Is this the right time to invest in Adani stocks?

“… going ahead with the issue will not be morally correct…” Gautam Adani, on Cancelled FPO Adani’s FPO was withdrawn,...

February 3, 2023
Adani Group: Mutual Fund Holdings
Stocks

Adani Group: Mutual Fund Holdings

Data as of 31.12.2022 Almost all the Adani stocks have seen reduced holdings, barring a few: 1. Adani Power: Only...

January 28, 2023
hdfc
Stocks

The Amalgamation of HDFC Ltd. and HDFC Bank: Is this a Skyscraping Deal?

On April 4, HDFC and HDFC Bank announced that their boards of directors had approved an all-stock merger of the...

November 4, 2022
ltd
Stocks

Food Wars: Devyani International Ltd vs. Restaurant Brands Asia Ltd vs. Jubilant FoodWorks Ltd.

Devyani International Ltd. Devyani International Limited (DIL) is a multifaceted quick-service restaurant (QSR) operator that was founded in 1991. It...

November 3, 2022
Next Post
financial

Financial skills to be learned from the women in our lives.

risk

Why is understanding your Risk Appetite important?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

Mamaearth

Beauty tycoon Mrs. Ghazal Alagh’s Mamaearth

April 26, 2023
growth

Growth vs. Value Investing.

January 28, 2022
devidend

Dividend Yield Mutual Funds.

January 21, 2022
PW Insider: July 2022 Edition

PW Insider: July 2022 Edition

August 20, 2022

subscRibe!

Categories

  • Books
    • Monthly Journal
  • Debt Fund
  • Equity Fund
  • Hybrid Fund
  • Large Cap
  • Learn
  • Mid Cap
  • Mutual Funds
  • Personal Finance
  • Savings
  • Small Cap
  • Stocks
  • Tax
  • Uncategorized

Instagram

    The Instagram Access Token is expired, Go to the Customizer > JNews : Social, Like & View > Instagram Feed Setting, to to refresh it.

About Us

MyGoalMySip is an Online Mutual fund investment platform powered by Prudent Wealth. As an investor, it might be hard to find the perfect investment opportunity; therefore, we’re here to help you make an informed decision.

Our goal is to educate people and make them financially literate, and at the same time guide you in your investment journey, in short MyGoalMySip is your investment buddy.

Read More
Facebook Twitter Youtube Linkedin

Quick Links

  • Books
  • Learn
  • Monthly journal
  • Merchandise

    Copyright © 2024 MygoalMySip | All Rights Reserved

    About Us

    MyGoalMySip is an Online Mutual fund investment platform powered by Prudent Wealth. As an investor, it might be hard to find the perfect investment opportunity; therefore, we’re here to help you make an informed decision.

    Our goal is to educate people and make them financially literate, and at the same time guide you in your investment journey, in short MyGoalMySip is your investment buddy.

    Read More
    Facebook Twitter Youtube Linkedin

    Quick Links

    • Books
    • Learn
    • Monthly journal
    • Merchandise

      Copyright © 2024 MygoalMySip | All Rights Reserved